Blinded independent central review of the progression-free survival endpoint
about
Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancyUS FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.Commentary: tackling the challenges of developing targeted therapies for cancer.Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.Estimation of discrete survival function for error-prone diagnostic tests.PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
P2860
Q34267149-305B9DBC-A569-4EF8-9457-9D3E496D329AQ34681668-B1100AD8-059D-4FF5-95BE-3065A7F637A9Q38066243-E65C997B-FE21-4435-8D83-2A4C248796B3Q38226264-B00E24A4-0533-4ED0-8BC0-17E7FAC89510Q38233353-BA2767F2-C9A1-4011-86B1-2973A80CB629Q38811063-03CE80E9-B0A4-4ECC-A4ED-6BC7D1B633ACQ39442153-25F6EC06-A677-4142-81C2-D2F81B552862Q39507513-4931B50E-493F-4284-88FC-3FC8DE6F6585Q41962742-C563736F-EA56-4D5D-B6DC-E4071BBB684CQ47141744-5F72C0EE-45CF-47E2-9D71-FF71D1F6BE09Q47409570-F08C9BB2-895A-4F8F-A670-04620B46E860Q48194466-C289106A-B9C2-49E5-A28F-DA7BAEE61EC9Q48345799-870B20F3-D7F3-4A5E-A0C4-7B140D9745D0Q58753938-B86437F1-E154-4C74-B90E-84081A899273
P2860
Blinded independent central review of the progression-free survival endpoint
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Blinded independent central review of the progression-free survival endpoint
@ast
Blinded independent central review of the progression-free survival endpoint
@en
type
label
Blinded independent central review of the progression-free survival endpoint
@ast
Blinded independent central review of the progression-free survival endpoint
@en
prefLabel
Blinded independent central review of the progression-free survival endpoint
@ast
Blinded independent central review of the progression-free survival endpoint
@en
P2093
P1433
P1476
Blinded independent central review of the progression-free survival endpoint
@en
P2093
Daniel Sargent
Nancy Roach
Will Bushnell
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0261
P50
P577
2010-01-01T00:00:00Z